NCT03320174Phase 2Completed

Long-Term Safety Study of Tafenoquine

Study sponsor: 60 Degrees Pharmaceuticals LLC

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov record CSV export · Pro

Primary completion2021-07-13Actual

Enrollment · participants600Actual

Source updated2026-04-17Last update listed in the registry record

Version history

Changes to this trial

Last 12 months

Pro unlocks the full available history and CSV export. View Pro features

No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.

Study details

Conditions studied

Healthy Volunteers

Treatments or interventions studied

TafenoquineDrug

Primary outcomes · main study measures

measure: Serious Ophthalmic Safety Event; description: Number of Participants with One or More protocol-defined serious ophthalmic safety event (SOSE) assessed by retinal changes from baseline using SD-OCT and qFAF. SOSE is assessed by significant retinal changes from baseline using SD-OCT and qFAF.; timeFrame: After 12 months of exposure to study drug

History coverage

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

How to read this history